Financial PerformanceAurinia reported third consecutive revenue beat this year with Lupkynis net product revenue incrementally above consensus, reinforcing confidence in achieving or possibly exceeding the net product revenue guidance of $210-220M.

Regulatory ApprovalAurinia announced that the Japanese Health Authorities have approved Lupkynis for the treatment of lupus nephritis, leading to an additional $10M milestone payment and potential royalties up to 20% on future sales in Japan.

Strategic OpportunitiesThe approval of Lupkynis in Japan could pave the way for an acquisition of Aurinia by Otsuka, marking a significant strategic development for the company.

Bears Say

Patent ProtectionThe longevity of the Lupkynis patent protection in the U.S. remains an uncertainty with maximum composition of matter patent term extension ending in October 2027.

Revenue And Market RisksKey risks to the price target include revenue growth below guidance or significantly below expectations, unforeseen safety issues, and IP challenges that reduce market exclusivity.

Strategic OpportunitiesAnalyst expresses disappointment that Aurinia will remain standalone, as more value could have been created with strategic synergies within a more established commercial organization.

---

Financials

Annual

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

8.71% Insiders

5.35% Mutual Funds

17.35% Other Institutional Investors

62.29% Public Companies and

Individual Investors

Detailed Ownership Overview >

0UJF FAQ

What was Aurinia Pharmaceuticals’s price range in the past 12 months?

Aurinia Pharmaceuticals lowest share price was C$15.41 and its highest was C$15.41 in the past 12 months.

What is Aurinia Pharmaceuticals’s market cap?

Currently, no data Available

When is Aurinia Pharmaceuticals’s upcoming earnings report date?

Aurinia Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 72 days.

How were Aurinia Pharmaceuticals’s earnings last quarter?

Aurinia Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported C$0.143 earnings per share for the quarter, beating the consensus estimate of C$0.021 by C$0.122.

Is Aurinia Pharmaceuticals overvalued?

According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals does not currently pay dividends.

What is Aurinia Pharmaceuticals’s EPS estimate?

Aurinia Pharmaceuticals’s EPS estimate is C$0.02.

How many shares outstanding does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals has 143,179,280 shares outstanding.

What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?

Aurinia Pharmaceuticals reported an EPS of C$0.143 in its last earnings report, beating expectations of C$0.021. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?

Currently, no hedge funds are holding shares in GB:0UJF

---

Aurinia Pharmaceuticals Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-5.78%

Trailing 12-Months

Asset Growth

-1.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

---

0UJF Earnings Call

Q3 2024

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong revenue growth and strategic progress, including significant milestones in product approvals and R&D. However, the restructuring and substantial workforce reduction indicate underlying challenges in operational efficiency and cost management, balancing the positive aspects.Read More>

---

0UJF Revenue Breakdown

90.33% Product revenue, net

9.67% License and contract revenue

---

0UJF Stock 12 Month Forecast

Average Price Target

C$14.82

▼(-3.80% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"C$11","16":"C$16","12.25":"C$12.25","13.5":"C$13.5","14.75":"C$14.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.86233,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$15.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.8240684,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$14.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.97827,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$12.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,12.25,13.5,14.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,15.444794615384616,15.47958923076923,15.514383846153846,15.549178461538462,15.583973076923076,15.618767692307692,15.653562307692308,15.688356923076924,15.723151538461538,15.757946153846154,15.79274076923077,15.827535384615384,{"y":15.86233,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,15.364928338461539,15.319856676923077,15.274785015384616,15.229713353846154,15.184641692307693,15.139570030769232,15.094498369230768,15.049426707692307,15.004355046153846,14.959283384615384,14.914211723076923,14.869140061538461,{"y":14.8240684,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.41,15.222943846153846,15.035887692307693,14.848831538461539,14.661775384615385,14.474719230769232,14.287663076923078,14.100606923076924,13.913550769230769,13.726494615384615,13.539438461538461,13.352382307692308,13.165326153846154,{"y":12.97827,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.41,"date":1703203200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.41,"date":1733443200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

FibroGen

―

OMER

Omeros

―

KNSA

Kiniksa Pharmaceuticals

―

MCRB

Seres Therapeutics

―

AUPH

Aurinia Pharmaceuticals

―

Compare GB:0UJF Stocks >

Best Analysts Covering 0UJF

1 Year

David Martin PhDBloom Burton

1 Year Success Rate

13/21 ratings generated profit

1 Year Average Return

+33.06%

reiterated a buy rating last month

Copying David Martin PhD's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +33.06% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Aurinia Pharmaceuticals (0UJF) Share Price & Analysis

0UJF Stock Chart & Stats

Aurinia Pharmaceuticals News

Bulls Say, Bears Say

Financials

Options Prices

Ownership Overview

0UJF FAQ

Aurinia Pharmaceuticals Stock Smart Score

Analyst Consensus

Blogger Sentiment

Insider Transactions

Technicals

Fundamentals

Company Description

Aurinia Pharmaceuticals

0UJF Earnings Call

0UJF Revenue Breakdown

0UJF Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering 0UJF

Become an Expert with TipRanks Premium